Sanofi (SNY: Quote,SNYNF.PK) and Pluromed Inc. announced that they have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts.
As part of the agreement, Sanofi will commercialize Pluromed's LeGoo, a highly innovative FDA approved and CE marked gel for temporary endovascular occlusion of blood vessels during surgical procedures.
Alison Lawton, senior vice president and general manager, Sanofi Biosurgery, commented, "The acquisition of Pluromed underscores Sanofi's commitment to strengthen its Biosurgery portfolio. LeGoo is a breakthrough technology with the potential to change the paradigm of vascular and cardiovascular surgical procedures, by providing fast, temporary control of blood flow while avoiding vessel trauma associated with standard of care."
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org